

Sangwoo Kim,<sup>a</sup> Michihiro Suga,<sup>a</sup>  
 Kyoko Ogasahara,<sup>a</sup> Terumi  
 Ikegami,<sup>b</sup> Yoshiko Minami,<sup>b</sup>  
 Toshitsugu Yubisui<sup>b</sup> and  
 Tomitake Tsukihara<sup>a\*</sup>

<sup>a</sup>Institute for Protein Research, Osaka University,  
 3-2 Yamada-oka, Suita, Osaka, Japan, and  
<sup>b</sup>Department of Biochemistry, Okayama  
 University of Science, 1-1 Ridai-cho,  
 Okayama 700-0005, Japan

Correspondence e-mail:  
 tsuki@protein.osaka-u.ac.jp

Received 22 January 2007  
 Accepted 7 March 2007

**PDB Reference:** *P. polycephalum* cytochrome  
*b*<sub>5</sub> reductase, 2eix, r12eixsf.

## Structure of *Physarum polycephalum* cytochrome *b*<sub>5</sub> reductase at 1.56 Å resolution

*Physarum polycephalum* cytochrome *b*<sub>5</sub> reductase catalyzes the reduction of cytochrome *b*<sub>5</sub> by NADH. The structure of *P. polycephalum* cytochrome *b*<sub>5</sub> reductase was determined at a resolution of 1.56 Å. The molecular structure was compared with that of human cytochrome *b*<sub>5</sub> reductase, which had previously been determined at 1.75 Å resolution [Bando *et al.* (2004), *Acta Cryst. D* **60**, 1929–1934]. The high-resolution structure revealed conformational differences between the two enzymes in the adenosine moiety of the FAD, the lid region and the linker region. The structural properties of both proteins were inspected in terms of hydrogen bonding, ion pairs, accessible surface area and cavity volume. The differences in these structural properties between the two proteins were consistent with estimates of their thermostabilities obtained from differential scanning calorimetry data.


### 1. Introduction

Cytochrome *b*<sub>5</sub> reductase (cyt *b*<sub>5</sub>R; EC 1.6.2.2), which is involved in the microsomal electron-transport system and erythrocyte function, catalyzes the two-electron transfer from NADH through FAD (flavin adenine dinucleotide; Strittmatter, 1965; Iyanagi *et al.*, 1984) to two molecules of cytochrome *b*<sub>5</sub>.

This enzyme is known to exist in two forms: a membrane-bound form and a soluble form. The membrane-bound form is composed of a hydrophobic domain (residues 1–25, MW ≈ 3 kDa) and a catalytic domain (residues 26–300, MW ≈ 30 kDa). The hydrophobic domain serves to anchor the protein to the microsome *via* strong noncovalent interactions with the lipid bilayer. The catalytic domain, which contains an active site and FAD, projects into the surrounding cytosol. This form is primarily embedded in the endoplasmic reticulum membrane as an amphipathic protein and participates in a variety of metabolic transformations, such as the desaturation (Oshino *et al.*, 1971) and elongation of fatty acids (Keyes & Cinti, 1980), cholesterol biosynthesis (Reddy *et al.*, 1977) and cytochrome P450-dependent hydroxylation reactions (Hildebrandt & Estabrook, 1971). The soluble form, which only contains the catalytic domain, is found in circulating erythrocytes, where it catalyzes methaemoglobin reduction in the electron-transport system (Hultquist & Passon, 1971).

Cyt *b*<sub>5</sub>R proteins have been identified in a wide range of eukaryotic genomes, including those of fungi (Csukai *et al.*, 1994), yeast (GenBank CAA86908), plants (Fukuchi-Mizutani *et al.*, 1999), nematodes (Kamath *et al.*, 2003), insects (Jones *et al.*, 2001), fish (GenBank BC045880), amphibians (Klein *et al.*, 2002), birds (GenBank AJ294706) and mammals (Strittmatter, 1965; Yubisui *et al.*, 1986). The structures of soluble cyt *b*<sub>5</sub>R proteins from pig (Nishida, Inaka & Miki, 1995; Nishida, Inaka, Yamanaki *et al.*, 1995), rat (Bewley *et al.*, 2001) and human (Bando *et al.*, 2004) have been determined using X-ray crystallography.

The slime mould *Physarum polycephalum*, a member of the myxomycetes, has a life cycle that includes a characteristic plasmodium phase during which the mould contains many nuclei but is not subdivided into cells. To grow, *P. polycephalum* has an unusual and





using *Origin* software from MicroCal for the curves, subtracting a thermogram of buffer alone obtained under identical conditions.

### 3. Results and discussion

#### 3.1. *P. polycephalum* cyt *b*<sub>5</sub>R structure


The three-dimensional structure of *P. polycephalum* cyt *b*<sub>5</sub>R was determined at 1.56 Å resolution. The final model included one protein molecule containing 243 amino-acid residues (Lys39–Phe281), one FAD molecule, one glycerol molecule, two iodide ions, one sodium ion and 237 water molecules in each crystallographic asymmetric unit. The first five residues of the protein (Glu34–Ser38) were invisible in the electron-density maps.

As shown in Fig. 1, the structure consists of two major domains: the N-terminal FAD-binding domain (Lys39–His144) and the C-terminal NADH-binding domain (Glu156–Phe281). The FAD-binding domain is a β-barrel consisting of six antiparallel β-strands (Fβ1–Fβ6) with a Greek-key motif. An α-helix (Fα1; Gly123–His131) and a short loop (Val119–Lys122) are attached to the β-barrel (Fig. 2). The NADH-binding domain has three βαβ motifs (Rossmann *et al.*, 1974, 1975). These domains are linked by the linker region (Gly145–Lys155), which is a random coil that may function as a hinge to allow efficient electron transfer of the reducing equivalents from the NADH molecule to the FAD molecule by correctly orienting the FAD- and NADH-binding domains (Bewley *et al.*, 2001; Davis *et al.*, 2004). The linker region is shorter than those of the cyt *b*<sub>5</sub>R proteins from higher eukaryotes (Figs. 2 and 3c), including the cyt *b*<sub>5</sub>R proteins from pig, rat and humans; these proteins have a larger 29-amino-acid linker region and three antiparallel β-strands are formed in the middle of the protein (Nishida, Inaka & Miki, 1995; Nishida, Inaka, Yamanaka *et al.*, 1995; Bewley *et al.*, 2001; Bando *et al.*, 2004). Phe147, Tyr149 and

Lys155 of the linker region interact with Gln84 of the FAD-binding domain and Asn179 and Asp249 of the NADH-binding domain, respectively.

The ‘lid region’ (Val119–Lys122; Fig. 2), which forms a surface-exposed loop, is nine residues shorter than the corresponding region in human cyt *b*<sub>5</sub>R (Fig. 3a). The protrusion of the lid from the Fα1 helix is smaller than that of human cyt *b*<sub>5</sub>R by approximately 5 Å. Tyr120 O forms hydrogen bonds with Gly123 N and Gln127 N<sup>ε2</sup>; Tyr120 N also forms a hydrogen bond with Ser126 O<sup>γ</sup>. These hydrogen bonds stabilize the loop structure of the lid.

The FAD molecule is located between the two domains, but primarily interacts with the FAD-binding domain. The flavin mononucleotide (FMN) moiety of *P. polycephalum* cyt *b*<sub>5</sub>R can be superposed on that of the human cyt *b*<sub>5</sub>R, whereas the adenine moieties of the two cyt *b*<sub>5</sub>R proteins have different orientations (Fig. 3). The riboflavin ring moiety is located in a predominantly hydrophobic pocket, where it makes van der Waals interactions with the Fβ4 strand (residues 85–101) and the Nα1 helix (residues 163–178); Fβ4 contains part of the FAD-binding motif (R<sub>x</sub>Y<sub>T</sub>X<sub>x</sub>S; residues 99–105) and Nα1 includes the NADH-binding motif (G<sub>x</sub>G<sub>x</sub>X<sub>P</sub>; residues 163–168). In addition to hydrophobic interactions, hydrogen bonds tightly fix the FAD molecule between the FAD- and the NADH-binding domains (Fig. 4), as has been observed in other cyt *b*<sub>5</sub>R proteins (Nishida, Inaka & Miki, 1995; Nishida, Inaka, Yamanaka *et al.*, 1995; Bewley *et al.*, 2001; Bando *et al.*, 2004). N3, N5 and O2 of the riboflavin-ring moiety form a hydrogen bond with Ile116 O, Thr167 O<sup>γ1</sup> and Lys118 N, respectively. The OP2 of the pyrophosphate moiety of FAD interacts with O<sup>γ</sup> and N of Ser126. AO3 of the ribose forms a hydrogen bond with Lys122 N. Unlike human cyt *b*<sub>5</sub>R, which has a hydrogen bond between AN6 of the adenine moiety and Phe113 N, the adenine moiety of *P. polycephalum* cyt *b*<sub>5</sub>R did not form any hydrogen bonds to the protein. The interaction between the FMN



**Figure 2** Sequence alignment of cyt *b*<sub>5</sub>R proteins from *P. polycephalum*, human, rat and pig. The secondary-structure elements are marked on top of the alignment: α-helices by a helix, β-strands by an arrow and turns by the letters TT. Conserved residues are boxed in white on a red background; similar residues are boxed in red with a white background. This figure was produced using *ClustalW*.






**Table 2**

The amino-acid compositions of the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins.

Residue	<i>P. polycephalum</i> cyt <i>b</i> <sub>5</sub> R		Human cyt <i>b</i> <sub>5</sub> R	
	No.	% of total residues	No.	% of total residues
Hydrophobic	124	51.0	143	52.0
Ala	10	4.1	12	4.4
Gly	19	7.8	19	6.9
Ile	18	7.4	22	8.0
Leu	16	6.6	25	9.1
Met	14	5.8	8	2.9
Phe	12	4.9	12	4.4
Pro	18	7.4	27	9.8
Trp	2	0.8	2	0.7
Val	15	6.2	16	5.8
Neutral	45	18.5	47	17.1
Asn	15	6.2	7	2.5
Cys	1	0.4	4	1.5
Gln	10	4.1	11	4.0
Ser	9	3.7	13	4.7
Thr	10	4.1	12	4.4
Hydrophilic	67	27.6	75	27.3
Arg	8	3.3	16	5.8
Asp	14	5.8	19	6.9
Glu	13	5.3	15	5.5
His	7	2.9	10	3.6
Lys	21	8.6	15	5.5
Tyr	11	4.5	10	3.6
Total No.	243		275	

moiety and the protein in *P. polycephalum* cyt *b*<sub>5</sub>R was similar to that observed in human cyt *b*<sub>5</sub>R.

To compare the structures of the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins, the structures of the two enzymes were superposed using the least-squares method. The root-mean-square deviations for each C<sup>α</sup> atom and for each side chain are given in Fig. 5. Although the overall structures clearly superposed with each other, local structural differences were detected in various regions, including Lys39–Asn45 (I), Ser106–Asp107 (II), Lys122 (III), Met153 (IV) and Pro257–Asn261 (V) (residue numbering based on *P. polycephalum* cyt *b*<sub>5</sub>R; Fig. 5). Lys122, Met153 and Pro257 are close to sites that are deleted in the proteins from lower eukaryotes compared with those from higher eukaryotes. The cause of the structural change at Ser106–Asp107 can be attributed to a difference in the hydrogen bonding of the residues. *P. polycephalum* cyt *b*<sub>5</sub>R preserves a hydrogen bond between Ser106 O<sup>γ</sup> and Glu109 N corresponding to the first of four hydrogen bonds (Ser98 O–Asp101 N, Asp99 O<sup>δ1</sup>–Gly71 N, Asp99 O<sup>δ2</sup>–Leu72 N and Asp101 O<sup>δ2</sup>–Ser98 N) in the human cyt *b*<sub>5</sub>R; the other



**Figure 5**

The r.m.s.d. in Å between common atoms from the corresponding residues of the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins. The deviations for the main-chain and side-chain atoms are indicated in red and blue, respectively. Residue numbering is based on *P. polycephalum* cyt *b*<sub>5</sub>R.

**Table 3**

Intramolecular ionic interactions of *P. polycephalum* and human cyt *b*<sub>5</sub>R.


Positive	Negative	Distance (Å)
<i>P. polycephalum</i> cyt <i>b</i> <sub>5</sub> R		
Arg40 N <sup>ε</sup>	Asp76 O <sup>δ1</sup>	2.82
Arg40 N <sup>η2</sup>	Asp76 O <sup>δ1</sup>	2.82
Arg68 N <sup>ε</sup>	Asp114 O <sup>δ1</sup>	2.76
Arg68 N <sup>η2</sup>	Asp114 O <sup>δ2</sup>	2.99
Arg201 N <sup>η1</sup>	Glu195 O <sup>ε2</sup>	2.76
Human cyt <i>b</i> <sub>5</sub> R		
Arg49 N <sup>η1</sup>	Glu131 O <sup>ε1</sup>	2.95
Arg49 N <sup>η2</sup>	Glu131 O <sup>ε2</sup>	2.92
Arg57 N <sup>η2</sup>	Glu131 O <sup>ε1</sup>	2.68
Arg58 N <sup>ε</sup>	Glu150 O <sup>ε1</sup>	2.65
Arg60 N <sup>ε</sup>	Asp106 O <sup>δ1</sup>	2.88
Arg60 N <sup>η2</sup>	Asp106 O <sup>δ2</sup>	2.95
Lys153 N <sup>ε</sup>	Asp196 O <sup>δ2</sup>	2.68
Arg218 N <sup>ε</sup>	Glu222 O <sup>ε2</sup>	2.93
Arg218 N <sup>η1</sup>	Glu212 O <sup>ε2</sup>	2.91
Arg258 N <sup>η2</sup>	Glu254 O <sup>ε2</sup>	2.76

three hydrogen bonds are lost, resulting in a different conformation from the human cyt *b*<sub>5</sub>R.

### 3.2. Structural features and thermostability of *P. polycephalum* and human cyt *b*<sub>5</sub>R

The stability of a protein depends on its structure and is an effective indicator of the core structure of a protein. We examined the thermal stability of the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins. The thermal denaturation of the proteins was monitored by DSC measurements at a scan rate of 1 K min<sup>-1</sup> in 10 mM phosphate buffer pH 7.6 (Fig. 6). The *P. polycephalum* and human cyt *b*<sub>5</sub>R protein solutions were turbid after heating, indicating that the heat denaturation of the proteins is not reversible under the conditions examined. Therefore, the data were not amenable to rigorous thermodynamic analysis. We then adopted the peak temperature on the DSC curve as the denaturation temperature (*T*<sub>m</sub>). The *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins exhibited *T*<sub>m</sub> values of 324.2 and 332.4 K, respectively; the denaturation temperature of the *P. polycephalum* cyt *b*<sub>5</sub>R was 8.2 K lower than that at which human cyt *b*<sub>5</sub>R denatures (Fig. 6).

Hydrogen bonds, ion pairs, accessible surface area (ASA) and cavity volume were examined in order to explore the structural features that resulted in the difference in the stabilities of the



**Figure 6**

DSC curves for the *P. polycephalum* (blue) and human (red) cyt *b*<sub>5</sub>R proteins.

**Table 4**

Estimation of the difference in stability of the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins based on the structural information.

$\Delta$ ASA represents the difference in the ASA between the native state and the denatured state of the enzymes. C/S and N/O represent nonpolar and polar atoms, respectively.  $\Delta\Delta G$  represents the difference in  $\Delta G$  between the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins.

	<i>P. polycephalum</i> cyt <i>b</i> <sub>5</sub> R	Human cyt <i>b</i> <sub>5</sub> R
Hydrophobicity		
$\Delta$ ASA (C/S) ( $\text{\AA}^2$ )	15789.7	17749.4
$\Delta$ ASA (N/O) ( $\text{\AA}^2$ )	6465.0	6925.8
$\Delta G_{\text{HP}}$ (kJ mol <sup>-1</sup> )	11.7	301.8
$\Delta\Delta G_{\text{HP}}$ (kJ mol <sup>-1</sup> )	-290.0	-
Cavity volume		
Cavity (probe 1.4 $\text{\AA}$ ) ( $\text{\AA}^3$ )	218.8	69.4
$\Delta G_{\text{CAV}}$ (kJ mol <sup>-1</sup> )	-11.4	-3.6
$\Delta\Delta G_{\text{CAV}}$ (kJ mol <sup>-1</sup> )	-7.8	-
Hydrogen bonds†	193 (0.79)	227 (0.83)
Ion pairs†	5 (0.021)	10 (0.036)
Total No. of residues	243	275

† Values in parentheses are the number per amino-acid residue.

enzymes. The *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins consist of 243 and 275 amino-acid residues, respectively. The amino-acid compositions ratios were similar for the two proteins (Table 2). Residues that formed ion pairs within 3.0  $\text{\AA}$  are listed in Table 3. The total numbers of hydrogen bonds and ion pairs within 3.0  $\text{\AA}$  in the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins were evaluated (Tables 3 and 4). The numbers of hydrogen bonds (0.79) and ion pairs (0.021) per amino-acid residue in *P. polycephalum* cyt *b*<sub>5</sub>R are slightly lower than those (0.83 and 0.036, respectively) in human cyt *b*<sub>5</sub>R.

Hydrophobic interactions are one of the important stabilizing forces of the folded conformation of proteins (Yutani *et al.*, 1977, 1987; Kellis *et al.*, 1988). The difference in the unfolding Gibbs energy change arising from hydrophobic effects ( $\Delta\Delta G_{\text{HP}}$ ) between the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins was estimated using the equation (Funahashi *et al.*, 2001)

$$\Delta\Delta G_{\text{HP}} \text{ (kJ mol}^{-1}\text{)} = 0.154 \text{ (kJ mol}^{-1}\text{ \AA}^{-2}\text{)} \times \Delta\Delta\text{ASA}_{\text{nonpolar}} \text{ (\AA}^2\text{)} \\ - 0.0254 \text{ (kJ mol}^{-1}\text{ \AA}^{-2}\text{)} \times \Delta\Delta\text{ASA}_{\text{polar}} \text{ (\AA}^2\text{)},$$

where  $\Delta\Delta\text{ASA}_{\text{nonpolar}}$  and  $\Delta\Delta\text{ASA}_{\text{polar}}$  are the differences between the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins in the change in the ASA of nonpolar and polar atoms, respectively, for all residues upon denaturation. The strength of the hydrophobic interactions ( $\Delta G_{\text{HP}}$ ) in *P. polycephalum* cyt *b*<sub>5</sub>R was 290.0 kJ mol<sup>-1</sup> lower than in human cyt *b*<sub>5</sub>R (Table 4). This indicates that compared with human cyt *b*<sub>5</sub>R, the weaker hydrophobic interactions in *P. polycephalum* cyt *b*<sub>5</sub>R are the basis of the lower denaturation temperature observed for this protein.

The compact packing of amino-acid residues results in a small cavity volume in the internal portion of a protein (Eriksson *et al.*, 1992). The difference in the energy contribution to protein stability arising from cavity size ( $\Delta G_{\text{CAV}}$ ) between the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins can be represented as (Funahashi *et al.*, 2001),

$$\Delta G_{\text{CAV}} \text{ (kJ mol}^{-1}\text{)} = -0.052 \text{ (kJ mol}^{-1}\text{ \AA}^{-3}\text{)} \times \Delta V \text{ (\AA}^3\text{)}.$$

Compared with human cyt *b*<sub>5</sub>R, the increase in the stabilization ( $\Delta G_{\text{CAV}}$ ) of *P. polycephalum* cyt *b*<sub>5</sub>R arising from the change in the cavity volume was -7.8 kJ mol<sup>-1</sup> (Table 4).

These results indicate that the difference in the hydrophobic interactions in the *P. polycephalum* and human cyt *b*<sub>5</sub>R proteins was the primary factor underlying the lower denaturation temperature of *P. polycephalum* cyt *b*<sub>5</sub>R, although differences in the internal packing of the two proteins contribute to the stability of the proteins.

## References

- Bando, S., Takano, T., Yubisui, T., Shirabe, K., Takeshita, M. & Nakagawa, A. (2004). *Acta Cryst.* **D60**, 1929–1934.
- Bewley, M. C., Marohnic, C. C. & Barber, M. J. (2001). *Biochemistry*, **40**, 13574–13582.
- Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T. & Warren, G. L. (1998). *Acta Cryst.* **D54**, 905–921.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- Csukai, M., Murray, M. & Orr, E. (1994). *Eur. J. Biochem.* **219**, 441–448.
- Davis, C. A., Crowley, L. J. & Barber, M. J. (2004). *Arch. Biochem. Biophys.* **431**, 233–244.
- Emsley, P. & Cowtan, K. (2004). *Acta Cryst.* **D60**, 2126–32.
- Eriksson, A. E., Baase, W. A., Zhang, X. J., Heinz, D. W., Blaber, M., Baldwin, E. P. & Matthews, B. W. (1992). *Science*, **255**, 178–183.
- Fukuchi-Mizutani, M., Mizutani, M., Tanaka, Y., Kusumi, T. & Ohta, D. (1999). *Plant Physiol.* **119**, 353–362.
- Funahashi, J., Takano, K. & Yutani, K. (2001). *Protein Eng.* **14**, 127–134.
- Hildebrandt, A. & Estabrook, R. W. (1971). *Arch. Biochem. Biophys.* **143**, 66–79.
- Hultquist, D. E. & Passon, P. G. (1971). *Nature New Biol.* **299**, 252–254.
- Ikegami, T., Kameyama, E., Yamamoto S., Minami, Y. & Yubisui, T. (2007). In the press.
- Iyanagi, T., Watanabe, S. & Anan, K. F. (1984). *Biochemistry*, **23**, 1418–1425.
- Jones, S. J., Riddle, D. L., Pouzyrev, A. T., Velculescu, V. E., Hillier, L., Eddy, S. R., Stricklin, S. L., Baillie, D. L., Waterston, R. & Marra, M. A. (2001). *Genome Res.* **11**, 1346–1352.
- Kamath, R. S., Fraser, A. G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., Le Bot, N., Moreno, S., Sohrmann, M., Welchman, D. P., Zipperlen, P. & Ahringer, J. (2003). *Nature (London)*, **421**, 231–237.
- Kellis, J. T., Nyberg, K., Sali, D. & Fersht, A. R. (1988). *Nature (London)*, **333**, 784–786.
- Keyes, S. R. & Cinti, D. L. (1980). *J. Biol. Chem.* **255**, 11357–11364.
- Klein, S. L., Strausberg, R. L., Wagner, L., Pontius, J., Clifton, S. W. & Richardson, P. (2002). *Dev. Dyn.* **225**, 384–391.
- Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). *J. Appl. Cryst.*, **26**, 283–291.
- McPherson, A. (1999). *Crystallization of Biological Macromolecules*. New York: Cold Spring Harbor Laboratory Press.
- Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). *Acta Cryst.* **D53**, 240–255.
- Nishida, H., Inaka, K. & Miki, K. (1995). *FEBS Lett.* **361**, 97–100.
- Nishida, H., Inaka, K., Yamanaka, M., Kaida, S., Kobayashi, K. & Miki, K. (1995). *Biochemistry*, **34**, 2763–2767.
- Oshino, N., Imai, Y. & Sato, R. (1971). *J. Biochem.* **69**, 155–167.
- Otwinowski, Z. & Minor, W. (1997). *Methods Enzymol.* **276**, 307–326.
- Reddy, V. V. R., Kupfer, D. & Capsi, E. (1977). *J. Biol. Chem.* **252**, 2797–2801.
- Rossmann, M. G. & Blow, D. M. (1962). *Acta Cryst.* **15**, 24–31.
- Rossmann, M. G., Liljas, A., Branden, C. I. & Banaszak, L. J. (1975). *The Enzymes*, 3rd ed., edited by P. D. Boyer, Vol. 11, pp. 61–102. New York: Academic Press.
- Rossmann, M. G., Moras, D. & Olsen, K. W. (1974). *Nature (London)*, **250**, 194–199.
- Shirabe, K., Yubisui, T. & Takeshita, M. (1989). *Biochim. Biophys. Acta*, **1008**, 189–192.
- Strittmatter, P. (1965). *J. Biol. Chem.* **240**, 4481–4487.
- Yubisui, T., Miyata, T., Iwanaga, S., Tamura, S. & Takeshita, M. (1986). *J. Biochem.* **99**, 407–422.
- Yutani, K., Ogasahara, K., Sugino, Y. & Matsusiro, A. (1977). *Nature (London)*, **267**, 274–275.
- Yutani, K., Ogasahara, K., Tsujita, T. & Sugino, Y. (1987). *Proc. Natl Acad. Sci. USA*, **84**, 4441–4444.